TICARCILLIN DISODIUM

US Previously Marketed

Details

Stereochemistry	ABSOLUTE
Molecular Formula	C15H14N2O6S2.2Na
Molecular Weight	428.391
Optical Activity	UNSPECIFIED
Defined Stereocenters	4 / 4
E/Z Centers	0
Charge	0

SHOW SMILES / InChI

Structure Search

SMILES

[Na+].[Na+].[H][C@]12SC(C)(C)[C@@H](N1C(=O)[C@H]2NC(=O)[C@H](C([O-])=O)C3=CSC=C3)C([O-])=O

InChI

InChIKey=ZBBCUBMBMZNEME-QBGWIPKPSA-L

InChI=1S/C15H16N2O6S2.2Na/c1-15(2)9(14(22)23)17-11(19)8(12(17)25-15)16-10(18)7(13(20)21)6-3-4-24-5-6;;/h3-5,7-9,12H,1-2H3,(H,16,18)(H,20,21)(H,22,23);;/q;2*+1/p-2/t7-,8-,9+,12-;;/m1../s1

HIDE SMILES / InChI

Molecular Formula	C15H14N2O6S2
Molecular Weight	382.411
Charge	-2
Count

Stereochemistry	ABSOLUTE
Additional Stereochemistry	No
Defined Stereocenters	4 / 4
E/Z Centers	0
Optical Activity	UNSPECIFIED

Molecular Formula	Na
Molecular Weight	22.9898
Charge	1
Count

Stereochemistry	ACHIRAL
Additional Stereochemistry	No
Defined Stereocenters	0 / 0
E/Z Centers	0
Optical Activity	NONE

Description
Sources: https://www.ncbi.nlm.nih.gov/pubmed/2387996 | https://www.drugs.com/pro/ticar.html

Ticarcillin (also known as Ticar) is a semisynthetic antibiotic with a broad spectrum of bactericidal activity against many gram-positive and gram-negative aerobic and anaerobic bacteria. Ticarcillin is not absorbed orally; therefore, it must be given intravenously or intramuscularly. Ticarcillin's antibiotic properties arise from its ability to prevent cross-linking of peptidoglycan during cell wall synthesis when the bacteria tries to divide, causing death. Usage of ticar was discontinued.

CNS Activity

Approval Year

Targets

Primary Target	Pharmacology	Condition	Potency
Bacterial penicillin-binding protein 233 Target ID: CHEMBL2354204 Sources: https://www.ncbi.nlm.nih.gov/pubmed/2387996	Inhibitor 8297

Conditions

Condition	Modality	Highest Phase	Product
Sepsis 71 Sources: https://www.drugs.com/pro/ticar.html	Curative	Approved 8429	TICAR Approved Use Unknown Launch Date 1976
Skin and soft tissue infections 33 Sources: https://www.drugs.com/pro/ticar.html	Curative	Approved 8429	TICAR Approved Use Unknown Launch Date 1976
Acute and chronic respiratory tract infections 6 Sources: https://www.drugs.com/pro/ticar.html	Curative	Approved 8429	TICAR Approved Use Unknown Launch Date 1976
Intra-abdominal infections 49 Sources: https://www.drugs.com/pro/ticar.html	Curative	Approved 8429	TICAR Approved Use Unknown Launch Date 1976
Infections of the female pelvis and genital tract 6 Sources: https://www.drugs.com/pro/ticar.html	Curative	Approved 8429	TICAR Approved Use Unknown Launch Date 1976

C_max

Value	Dose	Co-administered	Analyte	Population
324 μg/mL DRUG LABEL https://www.accessdata.fda.gov/drugsatfda_docs/label/2014/050590s069,050658s031lbl.pdf	3 g single, intravenous dose: 3 g route of administration: Intravenous experiment type: SINGLE co-administered: CLAVULANATE POTASSIUM	CLAVULANATE POTASSIUM	TICARCILLIN serum	Homo sapiens population: UNKNOWN age: ADULT sex: UNKNOWN food status: UNKNOWN
431.5 mg/L EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/3722046/	3 g single, intravenous dose: 3 g route of administration: Intravenous experiment type: SINGLE co-administered: CLAVULANIC ACID	CLAVULANIC ACID	TICARCILLIN serum	Homo sapiens population: HEALTHY age: ADULT sex: FEMALE / MALE food status: FASTED
621.8 mg/L EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/3722046/	5 g single, intravenous dose: 5 g route of administration: Intravenous experiment type: SINGLE co-administered: CLAVULANIC ACID	CLAVULANIC ACID	TICARCILLIN serum	Homo sapiens population: HEALTHY age: ADULT sex: FEMALE / MALE food status: FASTED
576.2 mg/L EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/3722046/	5 g single, intravenous dose: 5 g route of administration: Intravenous experiment type: SINGLE co-administered:		TICARCILLIN serum	Homo sapiens population: HEALTHY age: ADULT sex: FEMALE / MALE food status: FASTED

AUC

Value	Dose	Co-administered	Analyte	Population
485 μg × h/mL DRUG LABEL https://www.accessdata.fda.gov/drugsatfda_docs/label/2014/050590s069,050658s031lbl.pdf	3 g single, intravenous dose: 3 g route of administration: Intravenous experiment type: SINGLE co-administered: CLAVULANATE POTASSIUM	CLAVULANATE POTASSIUM	TICARCILLIN serum	Homo sapiens population: UNKNOWN age: ADULT sex: UNKNOWN food status: UNKNOWN
538 mg × h/L EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/3722046/	3 g single, intravenous dose: 3 g route of administration: Intravenous experiment type: SINGLE co-administered: CLAVULANIC ACID	CLAVULANIC ACID	TICARCILLIN serum	Homo sapiens population: HEALTHY age: ADULT sex: FEMALE / MALE food status: FASTED
890 mg × h/L EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/3722046/	5 g single, intravenous dose: 5 g route of administration: Intravenous experiment type: SINGLE co-administered: CLAVULANIC ACID	CLAVULANIC ACID	TICARCILLIN serum	Homo sapiens population: HEALTHY age: ADULT sex: FEMALE / MALE food status: FASTED
747 mg × h/L EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/3722046/	5 g single, intravenous dose: 5 g route of administration: Intravenous experiment type: SINGLE co-administered:		TICARCILLIN serum	Homo sapiens population: HEALTHY age: ADULT sex: FEMALE / MALE food status: FASTED
339 μg × h/mL DRUG LABEL https://www.accessdata.fda.gov/drugsatfda_docs/label/2014/050590s069,050658s031lbl.pdf	50 mg/kg bw single, intravenous dose: 50 mg/kg bw route of administration: Intravenous experiment type: SINGLE co-administered: CLAVULANATE POTASSIUM	CLAVULANATE POTASSIUM	TICARCILLIN serum	Homo sapiens population: UNKNOWN age: CHILD sex: UNKNOWN food status: UNKNOWN

T_1/2

Value	Dose	Co-administered	Analyte	Population
76 min EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/7140806/	5 g single, intravenous dose: 5 g route of administration: Intravenous experiment type: SINGLE co-administered:		TICARCILLIN plasma	Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: FASTED
1.1 h DRUG LABEL https://www.accessdata.fda.gov/drugsatfda_docs/label/2014/050590s069,050658s031lbl.pdf	3 g single, intravenous dose: 3 g route of administration: Intravenous experiment type: SINGLE co-administered: CLAVULANATE POTASSIUM	CLAVULANATE POTASSIUM	TICARCILLIN serum	Homo sapiens population: UNKNOWN age: ADULT sex: UNKNOWN food status: UNKNOWN
80.7 min EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/3722046/	3 g single, intravenous dose: 3 g route of administration: Intravenous experiment type: SINGLE co-administered: CLAVULANIC ACID	CLAVULANIC ACID	TICARCILLIN serum	Homo sapiens population: HEALTHY age: ADULT sex: FEMALE / MALE food status: FASTED
84.7 min EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/3722046/	5 g single, intravenous dose: 5 g route of administration: Intravenous experiment type: SINGLE co-administered: CLAVULANIC ACID	CLAVULANIC ACID	TICARCILLIN serum	Homo sapiens population: HEALTHY age: ADULT sex: FEMALE / MALE food status: FASTED
74.8 min EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/3722046/	5 g single, intravenous dose: 5 g route of administration: Intravenous experiment type: SINGLE co-administered:		TICARCILLIN serum	Homo sapiens population: HEALTHY age: ADULT sex: FEMALE / MALE food status: FASTED
1 h DRUG LABEL https://www.accessdata.fda.gov/drugsatfda_docs/label/2014/050590s069,050658s031lbl.pdf	50 mg/kg bw single, intravenous dose: 50 mg/kg bw route of administration: Intravenous experiment type: SINGLE co-administered: CLAVULANATE POTASSIUM	CLAVULANATE POTASSIUM	TICARCILLIN serum	Homo sapiens population: UNKNOWN age: CHILD sex: UNKNOWN food status: UNKNOWN

F_unbound

Value	Dose	Co-administered	Analyte	Population
55% DRUG LABEL https://www.accessdata.fda.gov/drugsatfda_docs/label/2014/050590s069,050658s031lbl.pdf	3 g single, intravenous dose: 3 g route of administration: Intravenous experiment type: SINGLE co-administered: CLAVULANATE POTASSIUM	CLAVULANATE POTASSIUM	TICARCILLIN serum	Homo sapiens population: UNKNOWN age: ADULT sex: UNKNOWN food status: UNKNOWN

Doses

Dose	Population	Adverse events
3 g 4 times / day multiple, intravenous Recommended Dose: 3 g, 4 times / day Route: intravenous Route: multiple Dose: 3 g, 4 times / day Co-administed with:: ciavuianate potassium iv(200 mg/kg/day) Sources: https://pubmed.ncbi.nlm.nih.gov/4073101 Page: p.90	unhealthy, 19-91 n = 37 Health Status: unhealthy Condition: Urinary tract infections Age Group: 19-91 Sex: M+F Population Size: 37 Sources: https://pubmed.ncbi.nlm.nih.gov/4073101 Page: p.90	Disc. AE: Rash, Nausea... Other AEs: Elevated liver enzymes, Eosinophilia... AEs leading to discontinuation/dose reduction: Rash (grade 1, 2.7%) Nausea (grade 2, 2.7%) Other AEs: Elevated liver enzymes Eosinophilia Sources: https://pubmed.ncbi.nlm.nih.gov/4073101 Page: p.90
80 mg/kg single, intravenous Highest studied dose Dose: 80 mg/kg Route: intravenous Route: single Dose: 80 mg/kg Sources: https://pubmed.ncbi.nlm.nih.gov/3777901 Page: p.360	healthy, 22-26 n = 8 Health Status: healthy Age Group: 22-26 Sex: M+F Population Size: 8 Sources: https://pubmed.ncbi.nlm.nih.gov/3777901 Page: p.360	Sources: https://pubmed.ncbi.nlm.nih.gov/3777901 Page: p.360
3 g 5 times / day multiple, intravenous Overdose Dose: 3 g, 5 times / day Route: intravenous Route: multiple Dose: 3 g, 5 times / day Co-administed with:: ciavuianate potassium iv(>100 mg) Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2014/050590s069,050658s031lbl.pdf Page: p.1	unhealthy Health Status: unhealthy Condition: Bacterial infections Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2014/050590s069,050658s031lbl.pdf Page: p.1	Other AEs: Convulsions... Other AEs: Convulsions Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2014/050590s069,050658s031lbl.pdf Page: p.1
3 g 5 times / day multiple, intravenous Recommended Dose: 3 g, 5 times / day Route: intravenous Route: multiple Dose: 3 g, 5 times / day Co-administed with:: ciavuianate potassium iv(100 mg) Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2014/050590s069,050658s031lbl.pdf Page: p.1	unhealthy Health Status: unhealthy Condition: Bacterial infections Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2014/050590s069,050658s031lbl.pdf Page: p.1	Other AEs: Hypersensitivity reaction, Diarrhea, Clostridium difficile... Other AEs: Hypersensitivity reaction (grade 3-5) Diarrhea, Clostridium difficile Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2014/050590s069,050658s031lbl.pdf Page: p.1

AEs

AE	Significance	Dose	Population
Elevated liver enzymes		3 g 4 times / day multiple, intravenous Recommended Dose: 3 g, 4 times / day Route: intravenous Route: multiple Dose: 3 g, 4 times / day Co-administed with:: ciavuianate potassium iv(200 mg/kg/day) Sources: https://pubmed.ncbi.nlm.nih.gov/4073101 Page: p.90	unhealthy, 19-91 n = 37 Health Status: unhealthy Condition: Urinary tract infections Age Group: 19-91 Sex: M+F Population Size: 37 Sources: https://pubmed.ncbi.nlm.nih.gov/4073101 Page: p.90
Eosinophilia		3 g 4 times / day multiple, intravenous Recommended Dose: 3 g, 4 times / day Route: intravenous Route: multiple Dose: 3 g, 4 times / day Co-administed with:: ciavuianate potassium iv(200 mg/kg/day) Sources: https://pubmed.ncbi.nlm.nih.gov/4073101 Page: p.90	unhealthy, 19-91 n = 37 Health Status: unhealthy Condition: Urinary tract infections Age Group: 19-91 Sex: M+F Population Size: 37 Sources: https://pubmed.ncbi.nlm.nih.gov/4073101 Page: p.90
Rash	grade 1, 2.7% Disc. AE	3 g 4 times / day multiple, intravenous Recommended Dose: 3 g, 4 times / day Route: intravenous Route: multiple Dose: 3 g, 4 times / day Co-administed with:: ciavuianate potassium iv(200 mg/kg/day) Sources: https://pubmed.ncbi.nlm.nih.gov/4073101 Page: p.90	unhealthy, 19-91 n = 37 Health Status: unhealthy Condition: Urinary tract infections Age Group: 19-91 Sex: M+F Population Size: 37 Sources: https://pubmed.ncbi.nlm.nih.gov/4073101 Page: p.90
Nausea	grade 2, 2.7% Disc. AE	3 g 4 times / day multiple, intravenous Recommended Dose: 3 g, 4 times / day Route: intravenous Route: multiple Dose: 3 g, 4 times / day Co-administed with:: ciavuianate potassium iv(200 mg/kg/day) Sources: https://pubmed.ncbi.nlm.nih.gov/4073101 Page: p.90	unhealthy, 19-91 n = 37 Health Status: unhealthy Condition: Urinary tract infections Age Group: 19-91 Sex: M+F Population Size: 37 Sources: https://pubmed.ncbi.nlm.nih.gov/4073101 Page: p.90
Convulsions		3 g 5 times / day multiple, intravenous Overdose Dose: 3 g, 5 times / day Route: intravenous Route: multiple Dose: 3 g, 5 times / day Co-administed with:: ciavuianate potassium iv(>100 mg) Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2014/050590s069,050658s031lbl.pdf Page: p.1	unhealthy Health Status: unhealthy Condition: Bacterial infections Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2014/050590s069,050658s031lbl.pdf Page: p.1
Diarrhea, Clostridium difficile		3 g 5 times / day multiple, intravenous Recommended Dose: 3 g, 5 times / day Route: intravenous Route: multiple Dose: 3 g, 5 times / day Co-administed with:: ciavuianate potassium iv(100 mg) Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2014/050590s069,050658s031lbl.pdf Page: p.1	unhealthy Health Status: unhealthy Condition: Bacterial infections Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2014/050590s069,050658s031lbl.pdf Page: p.1
Hypersensitivity reaction	grade 3-5	3 g 5 times / day multiple, intravenous Recommended Dose: 3 g, 5 times / day Route: intravenous Route: multiple Dose: 3 g, 5 times / day Co-administed with:: ciavuianate potassium iv(100 mg) Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2014/050590s069,050658s031lbl.pdf Page: p.1	unhealthy Health Status: unhealthy Condition: Bacterial infections Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2014/050590s069,050658s031lbl.pdf Page: p.1

Overview

CYP3A4	CYP2C9	CYP2D6	hERG

OverviewOther

Other Inhibitor	Other Substrate	Other Inducer
UGT2B15 64 ALDH 8 OAT1 599 OAT2 145 OATP1B3 706

Drug as perpetrator

Target	Modality	Activity
ALDH 8	inhibitor 3277 Sources: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6804443/	no
OAT2 147	inhibitor 3277 Sources: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6804443/	no
OATP1B3 715	inhibitor 3277 Sources: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6804443/	no
UGT2B15 64	inhibitor 3277 Sources: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6804443/	no
OAT1 603	inhibitor 3277 Sources: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6804443/	yes [IC50 1833 uM]

Sourcing

Vendor/Aggregator	ID	URL
ChEBI	CHEBI:9587	https://www.ebi.ac.uk/chebi/searchId.do?chebiId=CHEBI:9587
ChemicalBook	CB7224768	https://www.chemicalbook.com/ChemicalProductProperty_EN_CB7224768
ZINC	ZINC000003831540	http://zinc15.docking.org/substances/ZINC000003831540
eMolecules	29537804	https://www.emolecules.com/cgi-bin/more?vid=29537804

PubMed

Title	Date	PubMed
The relationships and susceptibilities of some industrial, laboratory and clinical isolates of Pseudomonas aeruginosa to some antibiotics and biocides.	2001 Dec	11851804
[Correlation between sensitivity to fosfomycin and the presence of penicillinase PSE-1 in Pseudomonas aeruginosa].	2001 Feb	11265218
Stability of piperacillin and ticarcillin in AutoDose infusion system bags.	2001 Nov	11724082
National shortages of antimicrobial agents: results of 2 surveys from the Infectious Diseases Society of America Emerging Infections Network.	2001 Nov 1	11588695
Systematic review and meta-analysis of antibiotic therapy for bone and joint infections.	2001 Oct	11871494
[Survey of the antibiotic sensitivity of Pseudomonas aeruginosa in France and the distribution of beta-lactam resistance mechanisms: the GERPB 1999 study].	2001 Sep	11642015
In vitro susceptibility of Stenotrophomonas maltophilia to various antimicrobial combinations.	2001 Sep-Oct	11687317
[Identification and susceptibility to antimicrobial agents of strictly anaerobic bacteria isolated from hospitalized patients].	2002	12632658
Once-daily, high-dose levofloxacin versus ticarcillin-clavulanate alone or followed by amoxicillin-clavulanate for complicated skin and skin-structure infections: a randomized, open-label trial.	2002 Aug 15	12145720
Antibiotic-associated maculopapular reaction.	2002 Dec	12494953
Mechanisms of beta-lactam resistance in Pseudomonas aeruginosa: prevalence of OprM-overproducing strains in a French multicentre study (1997).	2002 Dec	12461030
Antibiotic-induced recurring interstitial nephritis.	2002 Jan	11793135
Bacteriological evidence of antibiotic failure in pneumococcal lower respiratory tract infections.	2002 Jul	12168746
Geographic variations in activity of broad-spectrum beta-lactams against Pseudomonas aeruginosa: summary of the worldwide SENTRY Antimicrobial Surveillance Program (1997-2000).	2002 Jul	12106958
[Hepatic inflammatory pseudotumor regressing with antibiotic therapy].	2002 May 25	12148453
beta-Lactam allergenic determinants: fine structural recognition of a cross-reacting determinant on benzylpenicillin and cephalothin.	2002 Nov	12569987
Re-evaluations of disk diffusion quality control ranges for 11 drugs: report from the QC working group of the national committee for clinical laboratory standards.	2002 Oct	12385686
Natural antibiotic susceptibility of Enterobacter amnigenus, Enterobacter cancerogenus, Enterobacter gergoviae and Enterobacter sakazakii strains.	2002 Sep	12427217
Evaluation of ticarcillin/clavulanic acid versus ceftriaxone plus amikacin for fever and neutropenia in pediatric patients with leukemia and lymphoma.	2003 Apr	12959681
Natural antimicrobial susceptibilities of strains of 'unusual' Serratia species: S. ficaria, S. fonticola, S. odorifera, S. plymuthica and S. rubidaea.	2003 Apr	12654765
Early antibiotic selection and efficient rooting and acclimatization improve the production of transgenic plum plants (Prunus domestica L.).	2003 Aug	12827433
Antimicrobial susceptibility and synergistic activity of meropenem against Gram-negative non-fermentative bacteria isolated from cystic fibrosis patients.	2003 Dec	14998078
Late bacterial keratitis after implantation of intrastromal corneal ring segments.	2003 Feb	12648660
Agrobacterium radiobacter bacteremia in pediatric patients: case report and review.	2003 Feb	12586984
Antimicrobial susceptibility profile of molecular typed cystic fibrosis Stenotrophomonas maltophilia isolates and differences with noncystic fibrosis isolates.	2003 Feb	12526070
Dead bugs don't mutate: susceptibility issues in the emergence of bacterial resistance.	2003 Jan	12533275
Natural antibiotic susceptibility of strains of Serratia marcescens and the S. liquefaciens complex: S. liquefaciens sensu stricto, S. proteamaculans and S. grimesii.	2003 Jul	12842326
Cefepime versus ticarcillin and clavulanate potassium and aztreonam for febrile neutropenia therapy in high-dose chemotherapy patients.	2003 Jun	12796602
Beta-lactamase production in Prevotella and in vitro susceptibilities to selected beta-lactam antibiotics [corrected].	2003 Mar	12636990
Retrospective analysis of antibiotic susceptibility patterns of respiratory isolates of Pseudomonas aeruginosa in a Turkish University Hospital.	2003 Mar 7	12665428
[Assay of Acinetobacter SPP drug-resistance by Kirby-Bauer and Etest method].	2003 May	12754133
Sequence analysis and biochemical characterisation of chromosomal CAV-1 (Aeromonas caviae), the parental cephalosporinase of plasmid-mediated AmpC 'FOX' cluster.	2003 May 16	12757951
[Which betalactam antibiotic use as a marker of multiresistance in Pseudomonas aeruginosa?].	2003 Oct	14568590
Natural antimicrobial susceptibilities and biochemical profiles of Yersinia enterocolitica-like strains: Y. frederiksenii, Y. intermedia, Y. kristensenii and Y. rohdei.	2003 Sep 22	13129648
Beta-lactamase characterization in Escherichia coli isolates with diminished susceptibility or resistance to extended-spectrum cephalosporins recovered from sick animals in Spain.	2003 Summer	12820806
[Antibiotic susceptibility and occurrence of ESBL in Pseudomonas aeruginosa strains isolated from different clinical specimens].	2004	15773503
Detection and assay of beta-lactamases in clinical and non-clinical strains of Yersinia enterocolitica biovar 1A.	2004 Aug	15269194
[Pseudomonas aeruginosa: a multicentric study of antibiotic resistance (1999-2000)].	2004 Dec	15822507
[Surveillance on antibiotic resistance of Stenotrophomonas maltophilia in Chengdu and Chongqing area].	2004 Jan	14981826
[A 4-year study of Pseudomonas aeruginosa susceptibility to antibiotics (1998-2001) in northern Lebanon].	2004 Jul	15679237
Clinical significance of Roseomonas species isolated from catheter and blood samples: analysis of 36 cases in patients with cancer.	2004 Jun 1	15156446
Antibiotic resistance rates and phenotypes among isolates of Enterobacteriaceae in French extra-hospital practice.	2004 Mar	14986156
Antimicrobial resistance of selected Salmonella isolates from food animals and food in Alberta.	2005 Feb	15825516
Acinetobacter baumanii folliculitis in a patient with AIDS.	2005 May	15807684

Patents

Sample Use Guides

In Vivo Use Guide

Bacterial septicemia: 200 to 300 mg/kg/day by I.V. infusion in divided doses every 4 or 6 hours. Respiratory tract infections: (The usual dose is 3 grams given every 4 hours [18 grams/day] or 4 grams given every 6 hours [16 grams/day] depending on weight and the severity of the infection.) Urinary tract infections: Complicated: 150 to 200 mg/kg/day by I.V. infusion in divided doses every 4 or 6 hours. (Usual recommended dosage for average [70 kg] adults: 3 grams q.i.d.) Uncomplicated: 1 gram I.M. or direct I.V. every 6 hours.

Route of Administration: Other

In Vitro Use Guide

A total of 632 clinical bacterial isolates were tested for susceptibility to twofold dilutions of ticarcillin alone and in combination with 1, 2, and 4 micrograms of clavulanic acid (CA) (Timentin) per ml by a reference microdilution method. With the addition of CA, ticarcillin MICs were reduced eightfold or greater with 54 of 59 (92%) strains of the family Enterobacteriaceae with ticarcillin MICs of greater than or equal to 64 micrograms/ml. Ticarcillin MICs for beta-lactamase-producing Haemophilus influenzae, Neisseria gonorrhoeae, and most Staphylococcus aureus were reduced to less than or equal to 0.5 micrograms/ml when CA was added.

Substance Class	Chemical Created by `admin` on `Fri Dec 15 15:34:27 GMT 2023` Edited by `admin` on `Fri Dec 15 15:34:27 GMT 2023`
Record UNII	G8TVV6DSYG
Record Status	`Validated (UNII)`
Record Version

Download

Name

Type

Language

TICARCILLIN DISODIUM

Official Name

English

TICARPEN

Brand Name

English

NSC-759166

Code

English

TICARCILLIN DISODIUM SALT [MI]

Common Name

English

TICILLIN

Brand Name

English

BRL 2288

Code

English

TICARCILLIN SODIUM [JAN]

Common Name

English

BRL-2288

Code

English

TICARCILLIN DISODIUM [ORANGE BOOK]

Common Name

English

N-(2-Carboxy-3,3-dimethyl-7-oxo-4-thia-1-azabicyclo[3.2.0]hept-6-yl)-3-thiophenemalonamic acid disodium salt

Common Name

English

TICARCILLIN SODIUM [MART.]

Common Name

English

TICARCILLIN SODIUM

Common Name

English

TICARCILLIN DISODIUM SALT

Common Name

English

TICARCILLIN DISODIUM [USAN]

Common Name

English

TICARCILLIN SODIUM [EP MONOGRAPH]

Common Name

English

4-THIA-1-AZABICYCLO(3.2.0)HEPTANE-2-CARBOXYLIC ACID, 6-((CARBOXY-3-THIENYLACETYL)AMINO)-3,3-DIMETHYL-7-OXO-, DISODIUM SALT, (2S-(2.ALPHA.,5.ALPHA.,6.BETA.(S*)))-

Common Name

English

TICARCILLIN DISODIUM [USP MONOGRAPH]

Common Name

English

TICARCILLIN DISODIUM COMPONENT OF TIMENTIN

Common Name

English

TICARCILLIN SODIUM [EP IMPURITY]

Common Name

English

Ticarcillin disodium [WHO-DD]

Common Name

English

TICAR

Brand Name

English

MONAPEN

Brand Name

English

TICARCILLIN DISODIUM [GREEN BOOK]

Common Name

English

DISODIUM TICARCILLIN

Common Name

English

TIMENTIN COMPONENT TICARCILLIN DISODIUM

Common Name

English

Classification Tree Code System Code

NCI_THESAURUS

C1558